Rapamycin Longevity Protocol: What Attia and Sinclair Actually Take and Why

Rapamycin (also known as sirolimus) has the strongest preclinical lifespan-extension data of any pharmaceutical compound. Originally developed as an immunosuppressant for organ transplant patients, the Interventions Testing Program (NIA) showed roughly 9-14% lifespan extension in mice across multiple genetic backgrounds — a substantial signal in the standardized longevity-testing pipeline.

The off-label longevity use among physicians and longevity-medicine adults has been growing for the past 5-7 years. Peter Attia takes rapamycin. David Sinclair takes rapamycin. The Beacon Health / Dr. Alan Green community in New York has roughly 1,500 patients on off-label longevity rapamycin. So the question isn't whether it works in mice (it does) — it's what the human translation looks like, what dose, and what the risk profile actually is.

This is our honest read on the rapamycin longevity protocol — what the people actually taking it dose, the risk-benefit framework, and how to think about it as a longevity intervention.

What rapamycin does mechanistically

Rapamycin inhibits a protein complex called mTORC1 (mechanistic target of rapamycin complex 1). mTORC1 is the central nutrient-sensing pathway that drives anabolic processes — protein synthesis, cell growth, cell proliferation. When mTORC1 is active (you've just eaten a high-protein meal), the body builds new tissue. When mTORC1 is suppressed (fasting, caloric restriction, rapamycin), the body shifts to autophagy — recycling damaged cellular components.

Caloric restriction extends lifespan in virtually every model organism tested — partly by chronically suppressing mTORC1. Rapamycin produces a similar suppression pharmacologically. The longevity hypothesis is that intermittent or chronic mTORC1 suppression in adults produces the lifespan-extending autophagy effects of caloric restriction without requiring sustained dietary deprivation.

The actual longevity dosing protocols

Rapamycin's standard transplant-medicine dose is daily, producing continuous mTORC1 suppression and continuous immunosuppression. The longevity dosing approaches differ — they aim for intermittent mTORC1 suppression with minimal immune impact.

The intermittent dosing premise: weekly dosing produces transient mTORC1 suppression (3-4 days of activity from the half-life), which is enough to trigger autophagy benefits, without the chronic immunosuppression of daily dosing.

The risk framework

Rapamycin isn't a supplement — it's a prescription medication with real side effects and meaningful risk profile. The current human risk picture for off-label longevity use:

• Mouth sores (stomatitis): the most common side effect, ~20-30% of users at weekly dosing. Usually resolves with dose reduction.
• Mild lipid changes: rapamycin can elevate triglycerides and reduce HDL. Monitorable on standard panels.
• Glucose dysregulation: rapamycin can elevate fasting glucose acutely. Reverses on discontinuation.
• Infection susceptibility: the immunosuppressant case. Less of a concern at weekly dosing than daily, but real.
• Drug interactions: rapamycin interacts with multiple medications (statins, calcium channel blockers, others). Physician oversight is mandatory.

For most adults running the protocol with appropriate monitoring, side effects are manageable. But this is genuinely a medication that requires a knowledgeable prescribing physician.

Who shouldn't take rapamycin

• Adults trying to conceive or pregnant women
• Adults with active infections
• Adults on medications that interact (statins, immunosuppressants, certain antibiotics)
• Adults with poor diabetes control
• Adults who can't reliably access physician oversight for monitoring

The honest assessment

The preclinical data on rapamycin and longevity is the strongest of any pharmaceutical compound. The human translation is plausible but unproven — no human RCT has demonstrated lifespan extension yet (the PEARL trial is currently running). The off-label community of physicians and aggressive longevity adults running the protocol provides a body of empirical experience that the formal evidence base lags behind.

Our position: rapamycin is a reasonable bet for adults who:

1. Have access to a knowledgeable prescribing physician
2. Are willing to monitor lipid, glucose, and infection markers regularly
3. Understand the off-label nature and accept the uncertainty
4. Have already optimized the non-pharmaceutical longevity layers (sleep, diet, exercise, hormesis)

If any of those four conditions don't apply, rapamycin probably isn't the right next intervention. The risk-adjusted expected value tilts unfavorable without the foundation in place.

What pairs with rapamycin

The lifestyle layers that compound mTOR signaling work in the same direction as rapamycin — reduced protein intake (especially leucine), increased fasting, increased caloric restriction. Bryan Johnson's protocol specifically aligns mealtime around minimizing daily mTORC1 activation, with rapamycin providing weekly transient suppression on top.

For most adults: get the basics dialed first. Sleep architecture optimized. Mediterranean-pattern diet established. Sauna + cold + red light protocols running. NAD+ stack with TMG. THEN consider whether the additional ~10-15% lifespan-extension signal from rapamycin justifies the medication oversight overhead.

Going deeper

Disclosure: PureLongevity is an editorial publisher. We don't sell rapamycin or any pharmaceutical compound. This post is for educational/informational purposes only. Rapamycin is a prescription medication; off-label use requires physician oversight. We are not making medical recommendations — consult your physician before considering rapamycin or any prescription longevity intervention.